Swiss Medica Officially Announces Launch Of Breakthrough Product-O24 Fibromyalgia'TM'.
Swiss Medica Inc. (OTCBB:SWME) today officially launched its keenly anticipated O24 Fibromyalgia(TM) pain reliever during a joint press announcement with the National Fibromyalgia Association (NFA) at the National Association of Chain Drug Stores (NACDS) Marketplace conference in New Orleans.
O24 Fibromyalgia(TM) is the first product of its kind developed to specifically address the symptoms of long term pain associated with the fibromyalgia syndrome and is a patented and clinically tested, strong and safe, all-natural, over-the-counter health product. Swiss Medica is the owner, maker and distributor of this product. At today's press conference, Swiss Medica president Grant Johnson unveiled the packaging for the product - which he said will become available this summer at retail outlets throughout the United States and Canada.
As part of the launch, the company also announced a strategic partnership with the National Fibromyalgia Association (NFA). Lynne Matallana, the founder and president of the NFA, spoke about the plight of up to 11 million Americans living with the long-term pain caused by fibromyalgia - and explained why O24 Fibromyalgia(TM) pain reliever has become the first product to carry the NFA's new official Seal of Approval on its packaging. As part of this strategic partnership, the non-profit NFA will receive a percentage of the proceeds from the sale of O24 Fibromyalgia(TM). This revenue will directly benefit people with FM by supporting the programs and services of the NFA.
According to Lynne Matallana, president and founder of the National Fibromyalgia Association, the agreement will be a great benefit to her 400,000 members. "The fibromyalgia community is desperate for safe, effective treatment options to help reduce FM symptoms, including long-term widespread muscle pain," she said. "Even though there are up to 11 million Americans suffering with FM, there have been only a few products developed and clinically tested to evaluate their effectiveness specifically for fibromyalgia pain. We are pleased that Swiss Medica has not only developed such a product, but is now committed to helping support patient service programs and future research implemented by the NFA to directly benefit the FM community."
Fibromyalgia is typically characterized by widespread musculoskeletal aches, pain and stiffness, soft tissue tenderness, general fatigue and sleep disturbances. The most common sites of pain include the neck, back, shoulders, pelvic girdle and hands. Fibromyalgia patients experience a range of symptoms, varying in intensity that can fluctuate over time. The NFA estimates that the average family doctor sees at least one patient each day who is suffering from fibromyalgia and that the syndrome could be costing the U.S. economy as much as $10 billion a year in lost productivity.
The development of Swiss Medica's O24 Fibromyalgia(TM) pain reliever means that people living with FM no longer have to fight the pain of this condition on their own, using medications that are often ineffective - and sometimes have serious side effects.
Swiss Medica has worked closely with the NFA to better understand the needs of people living with fibromyalgia. The company's goals were to:
(1) Develop an effective product for this specific population of people who have had limited treatment options available to them;
(2) Make that product widely available in retail pharmacies; and,
(3) Work together with the NFA to create broad awareness of the fibromyalgia condition - and awareness of O24 Fibromyalgia(TM) as an approved, effective and safe treatment option.
"Now that these goals have been reached, as part of the product launch, Swiss Medica has become a key partner of the National Fibromyalgia Association (NFA)," said Mr. Johnson, president of Swiss Medica. "Working with the National Fibromyalgia Association will provide Swiss Medica with a unique opportunity to introduce our patented, safe, effective and completely natural pain relief technology to people with fibromyalgia. Today's announcement also provides a framework for us to make an unprecedented and on-going commitment to support the much-needed services that the NFA provides to fibromyalgia sufferers."
Mr. Johnson also discussed the previously-announced results of a recently completed randomized double blind clinical trial that compared the O24 Fibromyalgia(TM) pain reliever against a placebo on patients suffering fibromyalgia. This double blind clinical trial was conducted earlier this year by Dr. Gordon Ko (Head, Fibromyalgia Clinic) and Dr. David Berbrayer (Head, Dept. Rehabilitation Medicine) at Sunnybrook & Women's Health Sciences Centre (University of Toronto).
The pilot study, conducted over a four-to-six week period, compared the O24 Fibromyalgia(TM) pain reliever against a placebo in patients suffering with fibromyalgia. 68 (51%) used a placebo. The other 65 (49%) used the O24 Fibromyalgia(TM) product.
For participants who used O24 Fibromyalgia(TM), more than 90 per cent of the patients reported mild to markedly better improvement on the 7-point Lanier rating scale. Nearly 54% reported moderately better or markedly better results using O24 Fibromyalgia(TM) instead of the placebo. About 80% of the placebo group reported no change in their condition and 13% reported a worsening of their condition. Only 7% reported mild improvement from the placebo. The clinical study was statistically peer-reviewed by Marko Katic, biostatistician at the Institute of Clinical Evaluative Studies (ICES). Dr. Ko has submitted his findings to a peer-reviewed medical journal for publication and previewed the results of his study on Saturday May 28 in Victoria, British Columbia, Canada at the When the Body Forgets to Heal conference hosted by the Association of Complementary Physicians of B.C.
About the National Fibromyalgia Association
The National Fibromyalgia Association (previously known as the National Fibromyalgia Awareness Campaign) is a (501(C) 3) nonprofit organization whose mission is: To develop and execute programs dedicated to improving the quality of life for people with Fibromyalgia by increasing the awareness of the public, media, government and medical communities. The NFA is committed to efforts that will increase FM awareness and improve treatment options for people with Fibromyalgia. With teamwork and dedication, the NFA will continue to grow into a key organization helping people with FM everywhere.
About Swiss Medica Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at http://www.swissmedica.com, http://www.O24zone.com and http://www.pmsescape.com.
Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of pharmacies throughout the United States. Customers can also visit http://www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica also manufactures PMSEscape which holds US Patent #'s 5760014 and 5612320. PMSEscape is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit http://www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.
Swiss Medica Inc. (OTC Bulletin Board:SWME)
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 6, 2005|
|Previous Article:||Vanu, Inc. Named One of the 10 Coolest Companies by Telecommunications Magazine; Award to be given at Supercomm 2005.|
|Next Article:||The Exploration Company Updates Maverick Basin Operations.|